Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Throughout 2025, Vertex has operated in a persistently challenging environment shaped by fluctuating commodity prices, repeated tariff impositions, and subdued activity levels across our operating ...

Environmental Consulting net revenue increased by 7% compared to 2024. Environmental Consulting adjusted EBITDA (1) increased by 14% compared to 2024. Finance costs were reduced by 32% year-over-year ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining more than 100 points on Monday. Shares of Kimberly-Clark Corporation (NYSE:KMB) fell sharply in pre-market trading after the ...

https://www.thehindubusinessline.com/news/real-estate/unity-group-parsvnath-to-earn-120-crore-in-annual-rental-income-from-new-5-lakh-sq-ft-mall-in-delhi ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy Trikafta, a buyers club has resurfaced with a plan to introduce a discounted ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multitarget drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.